Text Size
22 studies found for:    "atypical hemolytic-uremic syndrome" OR "Hemolytic-Uremic Syndrome"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
2 Active, not recruiting An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
3 Recruiting Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention:
4 Active, not recruiting Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: eculizumab
5 Recruiting Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
Condition: Atypical Hemolytic Uraemic Syndrome.
Intervention:
6 Completed A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS)
Intervention:
7 Enrolling by invitation aHUS Observational Long Term Follow-Up
Condition: Atypical Hemolytic Uremic Syndrome
Intervention:
8 Active, not recruiting Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: eculizumab
9 Active, not recruiting Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: Eculizumab
10 Active, not recruiting Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
Condition: Atypical Hemolytic Uremic Syndrome
Intervention: Drug: Eculizumab
11 Recruiting The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS)
Intervention: Drug: Eculizumab
12 Completed To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
Condition: ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
Intervention:
13 Recruiting Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects
Conditions: Hemolytic-Uremic Syndrome;   Children;   Parents;   Psychological Adjustment
Intervention:
14 Completed Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
Conditions: Hemolytic-uremic Syndrome;   Escherichia Coli Infections
Intervention: Other: HUS standard coverage care (including in ICU)
15 Completed Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
Condition: Hemolytic Uremic Syndrome
Intervention: Drug: SYNSORB Pk
16 Unknown † Rituximab in Patients With Relapsed or Refractory TTP-HUS
Conditions: Thrombotic Thrombocytopenic Purpura;   Hemolytic Uremic Syndrome
Intervention: Drug: Rituximab
17 Completed The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
Conditions: Acute Renal Failure;   Chronic Kidney Failure;   Endothelial Dysfunction;   Hemolytic-uremic Syndrome (HUS)
Intervention:
18 Withdrawn The Plasma Large-Volume Exchange RCT
Conditions: Purpura, Thrombotic Thrombocytopenic;   Hemolytic Uremic Syndrome
Intervention: Procedure: Plasma Exchange
19 Enrolling by invitation International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
Conditions: Thrombotic Microangiopathy;   Hemolytic Uremic Syndrome;   Thrombotic Thrombocytopenic Purpura
Intervention:
20 Completed Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
Condition: Shiga-like Toxin-producing Escherichia Coli
Intervention: Drug: Eculizumab (Soliris®)
To Top

Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results
† Indicates status has not been verified in more than two years